Skip to main content
Print Save

Generic Latisse Availability

Last updated on Jun 8, 2022.

Latisse is a brand name of bimatoprost topical, approved by the FDA in the following formulation(s):

LATISSE (bimatoprost - solution/drops;topical)

  • Manufacturer: ALLERGAN
    Approval date: December 24, 2008
    Strength(s): 0.03% [RLD] [AT]

Has a generic version of Latisse been approved?

A generic version of Latisse has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Latisse and have been approved by the FDA:

bimatoprost solution/drops;topical

  • Manufacturer: AKORN
    Approval date: October 9, 2018
    Strength(s): 0.03% [AT]
  • Manufacturer: ALEMBIC PHARMS LTD
    Approval date: January 21, 2020
    Strength(s): 0.03% [AT]
  • Manufacturer: APOTEX INC
    Approval date: December 1, 2014
    Strength(s): 0.03% [AT]
  • Manufacturer: SANDOZ INC
    Approval date: April 19, 2016
    Strength(s): 0.03% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Latisse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of enhancing hair growth
    Patent 8,038,988
    Issued: October 18, 2011
    Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
    Assignee(s): Allergan, Inc.

    Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

    Patent expiration dates:

    • August 25, 2023
      ✓ 
      Patent use: TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Method of enhancing hair growth
    Patent 8,101,161
    Issued: January 24, 2012
    Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
    Assignee(s): Allergan, Inc.

    Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

    Patent expiration dates:

    • May 25, 2024
      ✓ 
      Patent use: METHOD OF STIMULATING HAIR GROWTH
    • May 25, 2024
      ✓ 
      Patent use: METHOD OF INCREASING HAIR GROWTH
  • Method of enhancing hair growth
    Patent 8,263,054
    Issued: September 11, 2012
    Inventor(s): Woodward; David F. & Vandenburgh; Amanda M
    Assignee(s): Allergan, Inc.

    Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
  • Method of enhancing hair growth
    Patent 8,632,760
    Issued: January 21, 2014
    Assignee(s): Allergan, Inc.

    Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING EYELASH GROWTH
  • Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
    Patent 8,758,733
    Issued: June 24, 2014
    Assignee(s): Allergan, Inc.

    The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING EYELASH GROWTH
  • Method of enhancing hair growth
    Patent 8,986,715
    Issued: March 24, 2015
    Assignee(s): Allergan, Inc.

    Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING HAIR GROWTH
  • Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
    Patent 9,216,183
    Issued: December 22, 2015
    Assignee(s): Allergan, Inc.

    The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING EYELASH GROWTH
  • Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
    Patent 9,226,931
    Issued: January 5, 2016
    Assignee(s): Allergan, Inc.

    The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.

    Patent expiration dates:

    • January 15, 2023
      ✓ 
      Patent use: METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AT Topical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer